Cargando…
Mining Gut Microbiota From Bariatric Surgery for MAFLD
The progression of metabolic dysfunction associated fatty liver disease (MAFLD) leads to steatohepatitis, liver fibrosis and hepatocellular carcinoma. Thus far, there have been no FDA-approved medications for MAFLD. Bariatric surgery (BS) has been found to improve insulin resistance, steatohepatitis...
Autores principales: | Wu, Wei-Kai, Chen, Yi-Hsun, Lee, Po-Chu, Yang, Po-Jen, Chang, Chin-Chen, Liu, Kao-Lang, Hsu, Cheng-Chih, Huang, Chi-Chang, Chuang, Hsiao-Li, Sheen, Lee-Yan, Liu, Chun-Jen, Wu, Ming-Shiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063105/ https://www.ncbi.nlm.nih.gov/pubmed/33897617 http://dx.doi.org/10.3389/fendo.2021.612946 |
Ejemplares similares
-
Emerging trends and hotspots in the links between the gut microbiota and MAFLD from 2002 to 2021: A bibliometric analysis
por: Li, Yixuan, et al.
Publicado: (2022) -
Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023) -
Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis
por: Luo, Kuanhong, et al.
Publicado: (2023) -
Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022) -
Evaluation of Abdominal Computed Tomography Scans for Differentiating the Discrepancies in Abdominal Adipose Tissue Between Two Major Subtypes of Primary Aldosteronism
por: Chen, Kuan-Ming, et al.
Publicado: (2021)